Literature DB >> 22137433

Animal models of lung cancer characterization and use for chemoprevention research.

Yian Wang1, Lucina Rouggly, Ming You, Ronald Lubet.   

Abstract

Of the potential sites of cancer development, cancer of the lung accounts for the highest number of cancer deaths each year in the United States (Jemal et al., 2010(1)). Based on its histopathological features, lung cancer is grouped into small cell lung cancer (SCLC; ∼20%) and non-SCLC (NSCLC; ∼80%), which is further divided into three subtypes: squamous cell carcinoma (∼30%), adenocarcinoma (∼50%), and large cell lung carcinoma. Every subtype of lung cancer has a relatively low 5-year survival rate that is attributed, in part, to the fact that they are routinely diagnosed at later histologic stages. Due to this alarming statistic, it is necessary to develop not only new and effective means of treatment but also of prevention. One of the promising approaches is chemoprevention which is the use of synthetic or natural agents to inhibit the initial development of or further progression of early lung lesions (Hong and Sporn, 1997). Many compounds have been identified as potentially effective chemopreventive agents using animal models. Most chemopreventive studies have been performed using mouse models which were developed to study lung adenomas or adenocarcinomas. More recently, models of squamous cell lung cancer and small cell lung cancer have also been developed. This review seeks to highlight mouse models which we helped to develop and presents the results of recent chemopreventive studies that we have performed in models of lung adenocarcinoma, squamous cell carcinoma, and small cell lung cancer.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22137433     DOI: 10.1016/B978-0-12-394596-9.00007-X

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  8 in total

1.  Dietary diindolylmethane suppresses inflammation-driven lung squamous cell carcinoma in mice.

Authors:  Jung Min Song; Xuemin Qian; Fitsum Teferi; Jing Pan; Yian Wang; Fekadu Kassie
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-17

Review 2.  Optimizing mouse models for precision cancer prevention.

Authors:  Clémentine Le Magnen; Aditya Dutta; Cory Abate-Shen
Journal:  Nat Rev Cancer       Date:  2016-02-19       Impact factor: 60.716

Review 3.  Bombesin-drug conjugates in targeted therapy for small cell lung cancer.

Authors:  Yichi Zhang; Elizabeth Holland; Anna Dinh; Duc Au; Lichun Sun
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

4.  Lung tumors in mice induced by "whole-life" inorganic arsenic exposure at human-relevant doses.

Authors:  Michael P Waalkes; Wei Qu; Erik J Tokar; Grace E Kissling; Darlene Dixon
Journal:  Arch Toxicol       Date:  2014-07-09       Impact factor: 5.153

5.  Honokiol inhibits lung tumorigenesis through inhibition of mitochondrial function.

Authors:  Jing Pan; Qi Zhang; Qian Liu; Steven M Komas; Balaraman Kalyanaraman; Ronald A Lubet; Yian Wang; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2014-09-22

6.  Organotypic culture of breast tumor explants as a multicellular system for the screening of natural compounds with antineoplastic potential.

Authors:  Irma Edith Carranza-Torres; Nancy Elena Guzmán-Delgado; Consuelo Coronado-Martínez; José Inocente Bañuelos-García; Ezequiel Viveros-Valdez; Javier Morán-Martínez; Pilar Carranza-Rosales
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

7.  The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.

Authors:  M-C Chen; C-H Chen; J-C Wang; A-C Tsai; J-P Liou; S-L Pan; C-M Teng
Journal:  Cell Death Dis       Date:  2013-09-19       Impact factor: 8.469

8.  Sex-related differences of urethane and sodium valproate effects on Ki-67 expression in urethane-induced lung tumors of mice.

Authors:  Donatas Stakišaitis; Raminta Mozūraitė; Dovilė Kavaliauskaitė; Lina Šlekienė; Ingrida Balnytė; Nomeda Juodžiukynienė; Angelija Valančiūtė
Journal:  Exp Ther Med       Date:  2017-04-12       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.